Ausgabe 5/2019
Inhalt (21 Artikel)
Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model
Kentaro Miyake, Tasuku Kiyuna, Kei Kawaguchi, Takashi Higuchi, Hiromichi Oshiro, Zhiying Zhang, Sintawat Wangsiricharoen, Sahar Razmjooei, Yunfeng Li, Scott D. Nelson, Takashi Murakami, Yukihiko Hiroshima, Ryusei Matsuyama, Michael Bouvet, Sant P. Chawla, Shree Ram Singh, Itaru Endo, Robert M. Hoffman
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation
Ou Yamaguchi, Kyoichi Kaira, Atsuto Mouri, Ayako Shiono, Kosuke Hashimoto, Yu Miura, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu
Potential drug–drug interactions and nephrotoxicity in hematopoietic stem cell transplant adult recipients during bone marrow transplantation unit stay
Lydia Sanchez, Astrid Bacle, Thierry Lamy, Pascal Le Corre
Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects
Chandra Prakash, Bin Fan, Syed Altaf, Sam Agresta, Hua Liu, Hua Yang
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer
Toshio Kawata, Mitsuo Higashimori, Yohji Itoh, Helen Tomkinson, Martin G. Johnson, Weifeng Tang, Fredrik Nyberg, Haiyi Jiang, Yusuke Tanigawara
SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS
Ian Joseph Cohen, Helen Toledano, Jerry Stein, Yehuda Kollender, Eyal Fenig, Osnat Konen, Zvi Bar-Sever, Josephine Issakov, Meora Feinmesser, Smadar Avigad, Shifra Ash
A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial
Kazuhiro Nishikawa, Kenta Murotani, Kazumasa Fujitani, Hitoshi Inagaki, Yusuke Akamaru, Shinya Tokunaga, Masakazu Takagi, Shigeyuki Tamura, Naotoshi Sugimoto, Tadashi Shigematsu, Takaki Yoshikawa, Tohru Ishiguro, Masato Nakamura, Hiroko Hasegawa, Satoshi Morita, Yumi Miyashita, Akira Tsuburaya, Junichi Sakamoto, Toshimasa Tsujinaka
Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia
Shaik Mohammad Naushad, Patchava Dorababu, Yedluri Rupasree, Addepalli Pavani, Digumarti Raghunadharao, Tajamul Hussain, Salman A. Alrokayan, Vijay Kumar Kutala
Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report
Emmanuelle Couty, Alexis Vallard, Sandrine Sotton, Sarra Ouni, Max-Adrien Garcia, Sophie Espenel, Chloe Rancoule, Majed Ben Mrad, Anne-Catherine Biron, Jean-Luc Perrot, Julien Langrand-Escure, Nicolas Magné
Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model
Daniel Thorpe, Masooma Sultani, Andrea Stringer
Determination of melphalan in human plasma by UPLC–UV method
Liusheng Huang, Vincent Cheah, Danna Chan, Florence Marzan, Christopher C. Dvorak, Francesca T. Aweeka, Janel Long-Boyle
Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer
Wei Zhang, Long Shi, Zhilong Zhao, Pingping Du, Xueshuai Ye, Dongbin Li, Zhenhua Cai, Jinsheng Han, Jianhui Cai
The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis
Liangfeng Chen, Xiaobing Han, Zhongzhou Hu, Liangxin Chen
The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men
Masaki Shiota, Naohiro Fujimoto, Shigehiro Tsukahara, Miho Ushijima, Ario Takeuchi, Eiji Kashiwagi, Junichi Inokuchi, Katsunori Tatsugami, Takeshi Uchiumi, Masatoshi Eto
CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy
Duo Liu, Xiang Li, Xuehua Li, Mingyan Zhang, Juan Zhang, Dan Hou, Zhiqiang Tong, Mei Dong
A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup
Carlo Lancia, Jakob K. Anninga, Matthew R. Sydes, Cristian Spitoni, Jeremy Whelan, Pancras C. W. Hogendoorn, Hans Gelderblom, Marta Fiocco
Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours
Peng Yuan, Jianzhong Shentu, Jianming Xu, Wendy Burke, Kate Hsu, Maria Learoyd, Min Zhu, Binghe Xu
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque, Martin Fuchs, Jorg Trojan, Mark Kozloff, Francesca Simionato, Ann Cleverly, Claire Smith, Shuaicheng Wang, Michael Man, Kyla E. Driscoll, Shawn T. Estrem, Michael M. F. Lahn, Karim A. Benhadji, Josep Tabernero
Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38
Mariko Iwase, Ken-ichi Fujita, Yuki Nishimura, Natsumi Seba, Yusuke Masuo, Hiroo Ishida, Yukio Kato, Yuji Kiuchi
Eligibility criteria for phase I clinical trials: tight vs loose?
Laeeq Malik, David Lu
The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma
Nicolas Albin, Adrien Monard, Jérémy Lapiere